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Disclaimer: This guideline is designed primarily as an educational resource for medical geneticists and other
health care providers to help them provide quality medical genetic services. Adherence to this guideline does
not necessarily assure a successful medical outcome. This guideline should not be considered inclusive of all
proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining
the same results. In determining the propriety of any speciﬁc procedure or test, the geneticist should apply his
or her own professional judgment to the speciﬁc clinical circumstances presented by the individual patient or
specimen. It may be prudent, however, to document in the patient’s record the rationale for any signiﬁcant
deviation from this guideline.
Abstract: Maternal serum screening for neural tube defects and fetal
aneuploidy in the second trimester has been incorporated into obstetrical
practice over the past two decades. Now, as a result of several multicenter
trials, ﬁrst trimester screening between 11 and 14 weeks has been shown to
be an effective and reliable screening test for Down syndrome and trisomy
18. This policy updates the American College of Medical Genetics policy
statement entitled Second Trimester Maternal Serum Screening for Fetal
Open Neural Tube Defects and Aneuploidy (2004), incorporates First
trimester diagnosis and screening for fetal aneuploidy (2008) and comple-
ments the sections of American College of Medical Genetic’s Standards
and Guidelines for Clinical Genetics Laboratories entitled Prenatal Screen-
ing for Down syndrome (2005) and Prenatal Screening for Open Neural
Tube Defects (2005). Genet Med 2009:11(11):818–821.
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S
creening tests to identify women at risk for fetal aneuploidy
such as trisomies 21 and 18, and fetal open neural tube
defects (ONTDs) are routinely offered to all women during
pregnancy regardless of maternal age. A number of screening
strategies are available, which utilize both biochemical and
ultrasonography to achieve high detection rates. Maternal serum
screening in the second trimester has now been available for
over two decades. More recently, ﬁrst trimester screening tests
offer women the opportunity of early screening for fetal aneu-
ploidy and the option of earlier diagnosis. Further, maternal age
35 is no longer recommended as a cutoff for determining which
patients should be offered invasive prenatal diagnostic testing.1
This current guideline supercedes the American College of
Medical Genetics (ACMG) policy statements entitled Second
Trimester Maternal Serum Screening for Fetal ONTDs and
Aneuploidy (2004) and First Trimester Diagnosis and Screening
for Fetal Aneuploidy (2008) and complements the sections of
ACMG’s Standards and Guidelines for Clinical Genetics Lab-
oratories entitled Prenatal Screening for ONTDs and Prenatal
Screening for Down syndrome (DS) (http://www.acmg.net).
SCREENING FOR NEURAL TUBE DEFECTS
In the 1980s, maternal serum screening programs became
available to identify pregnancies at risk for ONTDs and anen-
cephaly; 75–90% of ONTDs and 95% of anencephaly can be
detected by elevated maternal serum alphafetoprotein (MSAFP)
levels with a screen positive rate of 5% or less.2 MSAFP
screening may also detect 85% of ventral wall defects.3
The optimal time for NTD screening is 16–18 weeks’ ges-
tation, but screening can be done between 15 and 20 weeks.
Although NTD screening is optional, pregnancy management is
altered by the identiﬁcation of a fetal neural tube defect inde-
pendent of the patient’s decision to carry or discontinue her
pregnancy. The laboratory should be informed of the gestational
age at the time the sample was drawn for an accurate interpre-
tation. If there is a discrepancy in gestational age of 10 days
after an ultrasound examination, then the test result must be
reinterpreted.4 If the sample was drawn at 15 weeks, then a
new sample should be sent with the accurate gestational age.
Ultrasound dating of the pregnancy reduces the false-positive
rate and increases the detection rate of ONTDs. The test is most
accurate if the laboratory is also informed of maternal weight,
race (white or Black/African American), presence of insulin
dependent diabetes, number of fetuses, and family history of
ONTD. These factors are used to adjust the multiples of the
median (MoM) level. Cutoff levels for ONTD screening are
2.0–2.5 MoM in singleton pregnancies and 4.0–5.0 MoM in
twin pregnancies.4 However, the speciﬁc cutoff value is labo-
ratory dependent, and thus screen positive and screen negative
results are speciﬁed on reports. Genetic counseling and addi-
tional testing such as targeted ultrasound examination and/or
amniocentesis to evaluate amniotic ﬂuid AFP, and acetylcho-
linesterase levels are recommended for pregnancies with an
elevated MSAFP test result.5
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Historically, women 35 years or older at the time of delivery
and women with an abnormal screening test were offered pre-
natal genetic counseling and the option of a diagnostic test such
as amniocentesis or chorionic villus sampling (CVS). CVS is
performed in the ﬁrst trimester from 10 through 13 weeks’
gestation, whereas amniocentesis can be performed starting at
15 weeks’ gestation. CVS can be a transcervical or transabdom-
inal procedure. The risk of pregnancy loss with CVS is low;
some reports suggest this risk may be lower for transabdominal
procedures6; however, other reports suggest an equal loss rate
between the two procedures.7,8 Differences in loss rates if any
likely reﬂect operator experience with transcervical procedures
and available ultrasound technology. Contemporary literature
suggests that the risk of pregnancy loss from sonographically
directed amniocentesis is 1 in 300–600, with one study sug-
gesting that there may be no signiﬁcant increase over the
background miscarriage risk.8,9 Based on the relative safety of
these diagnostic procedures, the inability of screening tests to
detect all types of chromosomal abnormalities and in deference
to patient preference and autonomy, the American College of
Obstetricians and Gynecologists recommends that all pregnant
women, regardless of maternal age, should have the option of
invasive diagnostic testing. Diagnostic testing should be made
available, if requested, after appropriate counseling including
risks and beneﬁts.1,8
Maternal age alone is a poor screening criterion and there-
fore, for women who would like to further reﬁne their risk
before deciding whether or not to undergo invasive testing,
screening provides such an option. The current screening tests
used to adjust a woman’s age risk for trisomies 21 and 18 have
been shown to be highly effective and useful in several large,
prospective multicenter studies.10–14 These screening tests are
voluntary and, hence, women who do not want any information
regarding the chromosomal status of their fetus should not be
required to undergo testing or screening.
FIRST TRIMESTER SCREENING FOR FETAL
ANEUPLOIDY
The most effective screening test in the ﬁrst trimester uses a
combination of biochemical markers, pregnancy-associated
plasma protein A (PAPP-A) and human chorionic gonadotropin
(hCG), and the nuchal translucency (NT) measurement to adjust
a woman’s risk for trisomies 21 and 18. Collection of blood for
biochemical analysis is performed between 9 and 13 6/7 weeks’
gestation (crown rump length, 24–84 mm).15–17 Ultrasound
assessment of the NT measurement is performed between 11
and 13 6/7 weeks (crown rump length, 45–84 mm). In four
major studies, the DS detection rates range from 79 to 90% with
a 5% false-positive screen rate.11–14 Typically, PAPP-A levels
are reduced, and hCG is increased in trisomy 21. The overall
data suggest that free -hCG has slightly increased sensitivity
when compared with intact hCG.15 However, access to free
-hCG has been limited and therefore, many programs in the
United States use intact hCG. Free -hCG and intact hCG levels
are reduced in trisomy 18. Women who have ﬁrst trimester
screening and/or CVS should be offered MSAFP screening
between 15 and 20 weeks’ gestation and/or an ultrasound ex-
amination for the detection of NTDs between 15 and 20 weeks’
gestation.
NT refers to a clearly demarcated ﬂuid ﬁlled or sonolucent
space behind the fetal neck. This space is present in all fetuses.
An increased NT measurement is signiﬁcantly associated with
trisomy 21 and other forms of aneuploidy.16,17 NT measurement
alone has a detection rate for DS of 70% with a 5% falseposi-
tive rate. In general, NT measurement has limited usefulness as
a stand-alone test because of the increased sensitivity achieved
with incorporation of ﬁrst-trimester analytes or serum markers.1
Under some circumstances such as a NT measurement of 4 mm
or greater or a cystic hygroma where the addition of serum
markers in the ﬁrst trimester does not signiﬁcantly change the
risk for DS, and it is reasonable to offer the patient a diagnostic
test.18,19
Combined ﬁrst trimester serum screening for multifetal ges-
tations is less sensitive (70%) than in singleton pregnancies, and
there are concerns about averaging serum markers. NT measure-
ment alone yields similar detection rates for DS in multiple gesta-
tions. However, an increased or discordant NT may signify an
adverse pregnancy outcome particularly in monochorionic twins.20
Increased NT measurements are also associated with other fetal
structural anomalies including congenital heart defects, diaphrag-
matic hernias, skeletal dysplasias, and a variety of genetic syn-
dromes. Based on the current scientiﬁc evidence American College
of Obstetricians and Gynecologists recommends that patients with
a fetal NT measurement of 3.5 mm or higher should be offered a
targeted ultrasound, echocardiogram, or both.1
SECOND TRIMESTER SCREENING FOR FETAL
ANEUPOLOIDY
Multiple marker screening is used in the second trimester
(15–20 weeks) to screen for trisomies 21 and 18 as well as
ONTDs. The most widely used second trimester screening test
is the “quad screen,” so named because it uses four biochemical
markers—alphafetoprotein (AFP), hCG, unconjugated estriol
(uE3), and dimeric inhibin-A. Using a second trimester DS
cutoff risk of 1 in 270, the combination of maternal age and the
“quad screen” detects 75% of DS cases in women who are
younger than 35 years with a positive screening rate of 5% and
80% of the DS fetuses in women 35 years and older.21 In most
cases of DS, the AFP and uE3 levels are lower, whereas hCG
and dimeric inhibin-A levels are higher. The “triple test” that
relies on only three of the four analytes (AFP, hCG, and uE3)
has a sensitivity of 65% for DS and 70% for trisomy 18. In
most cases of trisomy 18, the levels of all three analytes are low.
Maternal serum screening in the second trimester has been
validated and is an appropriate screening test for both DS and
trisomy 18. In twin gestations, second trimester serum screening
detects only 50% of affected fetuses and can be difﬁcult to
interpret because a normal twin may mask the results of an affected
fetus.22 There are insufﬁcient prospective studies to determine
actual detection rates in a given program; thus, laboratories that
provide risk results are using mathematical models.
Multiple marker screening in the second trimester does not
reliably detect the other forms of aneuploidy that occur more
often as result of increasing maternal age, such as trisomy 13
and Klinefelter syndrome (47,XXY) (1 in 20,000 and 1 in 1000
livebirths, respectively). These would be detected on a routine
cytogenetic analysis of cultured amniocytes or villi.
Multiple marker screening can be performed at 15–20 weeks’
gestation. The laboratory must be informed of the gestational
age at the time the sample was drawn for an accurate interpre-
tation. The ﬁrst day of the last menstrual period is the most
common method for assessing gestational age, but ultrasound
measurement of the crown-rump length in the ﬁrst-trimester or
a biparietal diameter in the second trimester provides a more
accurate estimate of gestational age, within 7 and 10 days,
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ultrasound examination, then the test results must be reinter-
preted. If the sample was drawn at 15 weeks, a new sample
should be obtained and analyzed in accordance with the cor-
rected gestational age.23
Second trimester ultrasonography may identify fetal ana-
tomic defects, such as congenital heart defect or markers sug-
gestive of fetal aneuploidy like a thickened nuchal fold, absent
nasal bone, renal pyelectasis, or echogenic bowel. However,
these sonographic makers have a low sensitivity and speciﬁcity
for detecting aneuploidy; therefore, ultrasonography is not rec-
ommended as a primary screening tool for fetal aneuploidy.24,25
FIRST AND SECOND TRIMESTER SCREENING
FOR ANEUPLOIDY
There have been several different approaches proposed to
improve screening detection rates, which take advantage of both
ﬁrst and second trimester screening tests. Integrated screening
provides a single revised risk assessment based on the NT
measurement and PAPP-A in the ﬁrst trimester and the second
trimester quad screen. Studies have shown that this approach
has the highest detection rate for trisomy 21 (93–96%)11,13;
however, ﬁrst trimester results must be withheld until the test is
completed and, hence, a patient does not have the option of an
early diagnostic test in the event that the ﬁrst trimester results
would have indicated an increased risk for aneuploidy. Serum
integrated screening provides the patient with a single age-
adjusted risk assessment for trisomies 18 and 21 based on a ﬁrst
trimester PAPP-A and the second trimester serum screen. This
approach has a detection rate of 88% and is useful when a NT
measurement cannot be obtained, or in programs or communi-
ties where NT measurement is unavailable.26
Two sequential screening approaches, stepwise and contin-
gency, have been introduced to allow disclosure of results in the
ﬁrst trimester. Both have high detection rates (90%) with low
positive screening rates of 2–3%.27–29 By disclosing ﬁrst tri-
mester results in stepwise screening, a patient at high risk can
undergo a CVS and earlier termination in the event of an
affected fetus. A patient with a low or moderate risk after the
ﬁrst trimester screen proceeds to second trimester screening and
receives a ﬁnal revised risk assessment based on ﬁrst and
second trimester results. With contingency screening only those
women with a ﬁrst trimester screening result in a laboratory
determined intermediate range undergo testing in the second
trimester. Independent assessment of DS risk by ﬁrst and second
trimesters screening is discouraged because of the high false-
positive rates associated with this approach.11 It should be
emphasized that stated improved detection rates for all com-
bined methodologies discussed above are based on mathemat-
ical modeling techniques for combining ﬁrst and second trimes-
ter results, not large prospective cohort studies such as are
available for ﬁrst trimester alone or second trimester alone. A
disadvantage of the serum integrated or the sequential screening
approach is the real possibility that the patient may not return
for the second blood sample.30
RECOMMENDATIONS
The ACMG recommends the following.
● All women should have the option of invasive diagnostic
testing for fetal aneuploidy by CVS, if available, or am-
niocentesis. Beneﬁts include diagnosis of all major aneu-
ploidies and large chromosomal rearrangements.
● For women who do not initially want a diagnostic test,
screening for aneuploidy and ONTDs should be offered to
those who present for prenatal care before 20 weeks’ gesta-
tion regardless of maternal age. In cases where women do not
want information regarding fetal aneuploidy status, the reason
for declining screening should be documented.
● First trimester screening (NT measurement, PAPP-A, and
hCG) is an acceptable, effective approach for screening for
fetal aneuploidy if a woman presents early in pregnancy
(before 14 weeks’ gestation).
● Providers and/or centers that use aneuploidy screening
approaches based on a combination of ﬁrst and second
trimesters screening (integrated, serum integrated, and se-
quential) must be prepared to ensure that there is adequate
follow-up. If integrated screening is offered, they should
be certain that nondisclosure is acceptable to the patient.
Sequential or contingency screening with disclosure of
ﬁrst trimester results may be preferable for some providers
and patients.
● Women should be informed of the adjusted risk for aneu-
ploidy and allowed to make individual decisions regarding
diagnostic testing based on the numerical risk. Individuals
will weigh risk/beneﬁts surrounding diagnostic testing dif-
ferently.
● Women who decide to undergo ﬁrst trimester screening
and/or CVS should be offered MSAFP screening and/or an
ultrasound for the detection of neural tube defects between
15 and 20 weeks’ gestation.
● First trimester screening or second trimester screening can be
used in multifetal pregnancies; however, women should be
made aware of the limitations of screening in this setting.
● A NT measurement of 3.5 mm or greater, even in the
setting of a low risk for aneuploidy based on screening
results or a normal fetal karyotype, should alone prompt a
detailed anatomic ultrasound, echocardiogram or both.
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